<DOC>
	<DOCNO>NCT02125084</DOCNO>
	<brief_summary>The purpose study determine safety efficacy novel combination agent , enzalutamide everolimus , treatment patient metastatic castrate-resistant prostate cancer never receive prior chemotherapy , previously receive docetaxel chemotherapy progressive disease .</brief_summary>
	<brief_title>Enzalutamide Plus Everolimus Men With Metastatic Castrate-Resistant Prostate Cancer</brief_title>
	<detailed_description>This multi-center , open-label , Phase I study expansion cohort , patient metastatic Castrate-Resistant Prostate Cancer ( CRPC ) chemotherapy-naive previously receive docetaxel chemotherapy progressive disease time study entry . The dose escalation phase study establish optimum daily dose everolimus deliver along standard daily dose enzalutamide patient metastatic CRPC . Eligible patient must evaluable ( elevated PSA ) measurable disease ( per RECIST v1.1 ) . Following completion dose escalation phase , additional cohort patient treat maximum tolerate dose ( MTD ) give preliminary information regard efficacy combination .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>KEY POINTS : 1 . Adenocarcinoma prostate confirm histologically . 2 . Metastatic disease confirm biopsy imaging study . 3 . Castrateresistant prostate cancer ( i.e. , progression prostate cancer receive standard androgen ablation therapy , orchiectomy luteinizing hormonereleasing hormone [ LHRH ] antagonist ) . Castrate level serum testosterone must document progression patient orchiectomy . 4 . Chemotherapynaive previously treat docetaxel metastatic prostate cancer . 5 . ECOG 0 2 . 6 . Patients must progressive metastatic prostate cancer least 1 follow criterion : Progression measurable lesion define Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 . Bone progression define 2 new lesion bone scan . PSA progression determine minimum two rise PSA level interval 1 week great determination . The screen PSA measurement ( document progression ) must great equal 2 ng/mL . 7 . Adequate hematologic , hepatic renal function . 8 . Adequate coagulation parameter serum chemistry . 9 . Ability swallow retain oral medication . 10 . Life expectancy 6 month great . 11 . Ability understand nature study give write informed consent . 1 . Treatment 2 prior chemotherapy regimen . 2 . Previous treatment enzalutamide investigational androgen receptor inhibitor . 3 . Previous treatment PI3K/mTOR inhibitor . 4 . Known hypersensitivity everolimus rapamycins ( sirolimus , temsirolimus ) excipients . 5 . Use investigational drug within 21 day 5 halflives ( whichever short ) prior first dose study drug . For investigational drug 5 halflives less 21 day , minimum 10 day termination investigational drug administration study drug require . 6 . Most recent chemotherapy â‰¤21 day first dose study treatment and/or patient recover recent chemotherapy side effect prior study entry . 7 . CNS metastasis .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Metastatic Prostate Cancer</keyword>
	<keyword>Castrate-resistant</keyword>
	<keyword>Enzalutamide</keyword>
	<keyword>Everolimus</keyword>
</DOC>